Abstract: The present invention provides the use of PEG-IFN-? conjugates in association with ribavirin for the treatment of chronic hepatitis C infections. The present invention also provides a method for treating chronic hepatitis C infections in patients in need of such treating comprising administering an amount of PEG-IFN-? conjugate in association with an amount of ribavirin effective to treat hepatitis C.

Abstract: The present invention provides the use of PEG-IFN-? conjugates in association with ribavirin for the treatment of chronic hepatitis C infections. The present invention also provides a method for treating chronic hepatitis C infections in patients in need of such treating comprising administering an amount of PEG-IFN-? conjugate in association with an amount of ribavirin effective to treat hepatitis C.

Abstract: The present invention provides the use of PEG-IFN-&agr; conjugates in association with ribavirin for the treatment of chronic hepatitis C infections. The present invention also provides a method for treating chronic hepatitis C infections in patients in need of such treating comprising administering an amount of PEG-IFN-&agr;conjugate in association with an amount of ribavirin effective to treat hepatitis C.

Abstract: The present invention provides a method for treating chronic hepatitis C infections in patients in need of such treatment comprising administering an amount of IFN-&agr; in association with an amount of amantadine effective to treat hepatitis C. In accordance with the invention, IFN-&agr; and amantadine are administered at the same time or sequentially. The present invention also provides a kit for treating a hepatitis C infection containing IFN-&agr; and amantadine in suitable dosage forms for administering the combination therapy.

Abstract: A method of treating a patient infected with a hepatitis C virus to decrease the severity of the viral infection. The method comprises concomitantly administering over a given period of time to the patient a first component and a second component. The first component consists of a pharmaceutical composition containing as an active ingredient a pharmaceutically acceptable salt or prodrug of mycophenolic acid in a therapeutically effective amount to decrease the severity of the viral infection. The second component consists of an injection solution containing as an active ingredient interferon-&agr; or pegylated interferon-&agr; in a therapeutically effective amount to decrease the severity of the viral infection. The components are concomitantly administered over a period of time at least sufficient to reduce the amount of HCV-RNA present in the peripheral blood of said patient to less than 100 copies/ml at 24 weeks after the end of treatment.